A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.

Michigan Medicine is the only treatment center in Michigan and one of several dozen sites in the country to offer CAR T-cell immune-therapy for treating childhood leukemia.

In a new study, researchers looked for alterations in the gut microbiome to see whether its metabolites could improve outcomes after bone marrow transplants.